Zydus Lifesciences has achieved a significant regulatory milestone as the U.S. Food and Drug Administration (USFDA) granted Orphan Drug Designation (ODD) to its novel molecule Desidustat for the treatment of Sickle Cell Disease (SCD). The designation highlights the growing recognition of the urgent need for new and effective therapies in this rare and challenging condition.